Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 1998

View Archived Issues

Comparable antitumor effects of SEF-19 and CGS-20267 in rat breast cancer model

New anti-HIV option now available in the U.K.

DuPont Merck presents new anticoagulants

Dextrose in combination with nicotine patches may aid in smoking cessation

Ilex Oncology: Q1 1998 highlights

AIDS vaccine produces immune response but fails to protect against challenge with chimeric SIV

ONYX-015: phase I and II results in various cancers discussed at ASCO

Topical NGF demonstrates efficacy in the treatment of corneal ulcers

Intron A/Rebetol combination shows promise in treatment-naive patients

T-593 exhibits antiulcer activity via a dual mechanism of action

GVAX induces immune responses in prostate cancer patients

Company Profile: Dovetail Technologies

Rabbit Ab appears to be more effective than horse Ab in the prevention of graft rejection

Phytopharm's osteoarthritis drug enters phase II

SmithKline Beecham and Leo will collaborate on dermatological R&D

Matritech's colon cancer test denied 510(k) marketing clearance

Boehringer Ingelheim prepares novel immunomodulators

Merck KGaA synthesizes new series of PDE IV inhibitors

Heterocyclic cholesterol biosynthesis inhibitors discovered at Zeneca

Research at Kowa leads to potent inhibitors of IgE antibody production

Phosphonate nucleotides with antiviral/antitumor activity from Mitsubishi

Optison approved in E.U.

New P2Y1 antagonist will facilitate further study of the receptor and its physiological role

Yamanouchi and Merck KGaA to codevelop cardiovascular drugs

IRFI-117, an adenosine A1 antagonist for oral or i.v. dosing

NO-releasing NSAID protects against gastric mucosal damage: in vitro and in vivo studies

Alosetron emerging as safe and effective treatment for IBS in female patients

New penems in development at Menarini and Lusofarmaco

Merck & Co. sells interest in DuPont Merck to DuPont

IRFI-165, an adenosine antagonist for the treatment of depression

Favorable preliminary phase I/II trials results reported at ASCO for Titan's cancer vaccines

97% response rate for Rituxan + CHOP in small pilot trial in intermediate- or high-grade NHL

Fiblast North American stroke trial suspended